Biotech | April 10, 2022
LivaNova initiates targeted commercial launch of Essenz patient monitor
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Deploying solutions like Uniphore’s U-Self Serve and U-Assist with SpinSci’s Patient Engage and Patient Assist is an important step forward in creating frictionless patient experiences
Subscribe To Our Newsletter & Stay Updated
